Biotech News

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

Annexon, Inc. (ANNX)Annexon, Inc.2026-07-14 20:05 ESTClinical readout

BRISBANE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced an oral presentation

Related news

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

BTAIBioXcel2026-05-28 11:00 EST

BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting

NBIXNeurocrine Biosciences2026-07-01 20:05 EST

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

ALKSAlkermes plc2026-06-04 11:00 EST

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

GHRSGH Research2026-06-04 11:00 EST

GH Research Announces Publication of Phase 2a Postpartum Depression Results

DNLIDenali Therapeutics2026-05-21 22:00 EST

Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease

HRMYHarmony Biosciences2026-08-04 11:30 EST

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

AXSMAxsome2026-07-07 11:00 EST

Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)

AXSMAxsome2026-06-26 11:00 EST

Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)

View all latest news

Annexon, Inc.

Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic and autoimmune diseases. Vonaprument Vonaprument is a complement inhibitor in pivotal development for geographic atrophy, an advanced form of dry...

Recent company news

ANNXAnnexon, Inc.2026-08-06 12:00 EST

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

ANNXAnnexon, Inc.2026-07-30 20:01 EST

Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance

ANNXAnnexon, Inc.2026-07-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ANNXAnnexon, Inc.2026-07-14 20:05 EST

Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026

ANNXAnnexon, Inc.2026-06-16 20:05 EST

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close: 5.60 USD
Market cap: 861.81M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States